NB-IRBESARTAN HCT DIN 02570238
Health Canada record
| Active ingredient(s) | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 12.5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C09DA04 IRBESARTAN AND DIURETICS |
| Original market date | |
| Current status date | 22-Jul-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
NB Pharma Inc. — licence 3-002798, currently licensed, last inspection rating C (2025-12-05).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing IRBESARTAN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02241819 | AVALIDE | SANOFI-AVENTIS CANADA INC | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Marketed |
| 02241818 | AVALIDE | SANOFI-AVENTIS CANADA INC | Tablet | IRBESARTAN 150 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Marketed |
| 02237925 | AVAPRO | SANOFI-AVENTIS CANADA INC | Tablet | IRBESARTAN 300 MG | Marketed |
| 02237924 | AVAPRO | SANOFI-AVENTIS CANADA INC | Tablet | IRBESARTAN 150 MG | Marketed |
| 02372371 | IRBESARTAN | SANIS HEALTH INC | Tablet | IRBESARTAN 150 MG | Marketed |
| 02372398 | IRBESARTAN | SANIS HEALTH INC | Tablet | IRBESARTAN 300 MG | Marketed |
| 02385295 | IRBESARTAN | SIVEM PHARMACEUTICALS ULC | Tablet | IRBESARTAN 150 MG | Marketed |
| 02385333 | IRBESARTAN HCT | SIVEM PHARMACEUTICALS ULC | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Marketed |
| 02545241 | JAMP IRBESARTAN | JAMP PHARMA CORPORATION | Tablet | IRBESARTAN 300 MG | Marketed |
| 02545225 | JAMP IRBESARTAN | JAMP PHARMA CORPORATION | Tablet | IRBESARTAN 75 MG | Marketed |
| 02545233 | JAMP IRBESARTAN | JAMP PHARMA CORPORATION | Tablet | IRBESARTAN 150 MG | Marketed |
| 02423006 | MINT-IRBESARTAN | MINT PHARMACEUTICALS INC | Tablet | IRBESARTAN 300 MG | Marketed |
| 02422999 | MINT-IRBESARTAN | MINT PHARMACEUTICALS INC | Tablet | IRBESARTAN 150 MG | Marketed |
| 02422980 | MINT-IRBESARTAN | MINT PHARMACEUTICALS INC | Tablet | IRBESARTAN 75 MG | Marketed |
| 02570246 | NB-IRBESARTAN HCT | NB PHARMA INC. | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Approved |
| 02570211 | NB-IRBESARTAN HCT | NB PHARMA INC. | Tablet | IRBESARTAN 150 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Approved |
| 02317087 | PMS-IRBESARTAN | PHARMASCIENCE INC | Tablet | IRBESARTAN 300 MG | Marketed |
| 02317060 | PMS-IRBESARTAN | PHARMASCIENCE INC | Tablet | IRBESARTAN 75 MG | Marketed |
| 02317079 | PMS-IRBESARTAN | PHARMASCIENCE INC | Tablet | IRBESARTAN 150 MG | Marketed |
| 02328534 | PMS-IRBESARTAN-HCTZ | PHARMASCIENCE INC | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Marketed |
| 02328526 | PMS-IRBESARTAN-HCTZ | PHARMASCIENCE INC | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Marketed |
| 02328518 | PMS-IRBESARTAN-HCTZ | PHARMASCIENCE INC | Tablet | IRBESARTAN 150 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Marketed |
| 02365219 | PRO-IRBESARTAN | PRO DOC LIMITEE | Tablet | IRBESARTAN 300 MG | Marketed |
| 02365162 | PRO-IRBESARTAN-HCTZ | PRO DOC LIMITEE | Tablet | IRBESARTAN 150 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Marketed |
| 02328488 | SANDOZ IRBESARTAN | SANDOZ CANADA INCORPORATED | Tablet | IRBESARTAN 150 MG | Marketed |
| 02328496 | SANDOZ IRBESARTAN | SANDOZ CANADA INCORPORATED | Tablet | IRBESARTAN 300 MG | Marketed |
| 02328461 | SANDOZ IRBESARTAN | SANDOZ CANADA INCORPORATED | Tablet | IRBESARTAN 75 MG | Marketed |
| 02337436 | SANDOZ IRBESARTAN HCT | SANDOZ CANADA INCORPORATED | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Marketed |
| 02337428 | SANDOZ IRBESARTAN HCT | SANDOZ CANADA INCORPORATED | Tablet | IRBESARTAN 150 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Marketed |
| 02337444 | SANDOZ IRBESARTAN HCT | SANDOZ CANADA INCORPORATED | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Marketed |
| 02406837 | SPC-IRBESARTAN | SUN PHARMA CANADA INC | Tablet | IRBESARTAN 300 MG | Marketed |
| 02406810 | SPC-IRBESARTAN | SUN PHARMA CANADA INC | Tablet | IRBESARTAN 75 MG | Marketed |
| 02406829 | SPC-IRBESARTAN | SUN PHARMA CANADA INC | Tablet | IRBESARTAN 150 MG | Marketed |
| 02330539 | TEVA-IRBESARTAN HCTZ | TEVA CANADA LIMITED | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Marketed |
| 02328100 | ACT IRBESARTAN | ACTAVIS PHARMA COMPANY | Tablet | IRBESARTAN 300 MG | Cancelled Post Market |
| 02328089 | ACT IRBESARTAN | ACTAVIS PHARMA COMPANY | Tablet | IRBESARTAN 150 MG | Cancelled Post Market |
| 02328070 | ACT IRBESARTAN | ACTAVIS PHARMA COMPANY | Tablet | IRBESARTAN 75 MG | Cancelled Post Market |
| 02357410 | ACT IRBESARTAN/HCT | ACTAVIS PHARMA COMPANY | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Cancelled Post Market |
| 02357399 | ACT IRBESARTAN/HCT | ACTAVIS PHARMA COMPANY | Tablet | IRBESARTAN 150 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Cancelled Post Market |
| 02386976 | APO-IRBESARTAN | APOTEX INC | Tablet | IRBESARTAN 150 MG | Dormant |
| 02373335 | AVA-IRBESARTAN | AVANSTRA INC | Tablet | IRBESARTAN 300 MG | Cancelled Post Market |
| 02372231 | DOM-IRBESARTAN-HCTZ | DOMINION PHARMACAL | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Cancelled Pre Market |
| 02372223 | DOM-IRBESARTAN-HCTZ | DOMINION PHARMACAL | Tablet | IRBESARTAN 150 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Cancelled Pre Market |
| 02433834 | IRBESARTAN | ACTAVIS PHARMA COMPANY | Tablet | IRBESARTAN 150 MG | Cancelled Pre Market |
| 02433842 | IRBESARTAN | ACTAVIS PHARMA COMPANY | Tablet | IRBESARTAN 300 MG | Cancelled Pre Market |
| 02434296 | IRBESARTAN/HCT | ACTAVIS PHARMA COMPANY | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Cancelled Pre Market |
| 02372908 | IRBESARTAN/HCTZ | SANIS HEALTH INC | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Dormant |
| 02418215 | JAMP-IRBESARTAN | JAMP PHARMA CORPORATION | Tablet | IRBESARTAN 300 MG | Cancelled Post Market |
| 02347326 | MYLAN-IRBESARTAN | MYLAN PHARMACEUTICALS ULC | Tablet | IRBESARTAN 300 MG | Cancelled Post Market |
| 02376903 | MYLAN-IRBESARTAN HCTZ | MYLAN PHARMACEUTICALS ULC | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Cancelled Pre Market |
| 02368978 | NTP-IRBESARTAN | TEVA CANADA LIMITED | Tablet | IRBESARTAN 75 MG | Cancelled Pre Market |
| 02368994 | NTP-IRBESARTAN | TEVA CANADA LIMITED | Tablet | IRBESARTAN 300 MG | Cancelled Pre Market |
| 02363224 | RAN-IRBESARTAN HCTZ | RANBAXY PHARMACEUTICALS CANADA INC. | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 25 MG | Cancelled Post Market |
| 02363208 | RAN-IRBESARTAN HCTZ | RANBAXY PHARMACEUTICALS CANADA INC. | Tablet | IRBESARTAN 150 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Cancelled Post Market |
| 02425335 | RIVA-IRBESARTAN | LABORATOIRE RIVA INC. | Tablet | IRBESARTAN 300 MG | Cancelled Post Market |
| 02316005 | TEVA-IRBESARTAN | TEVA CANADA LIMITED | Tablet | IRBESARTAN 300 MG | Cancelled Post Market |
| 02316390 | TEVA-IRBESARTAN | TEVA CANADA LIMITED | Tablet | IRBESARTAN 75 MG | Cancelled Post Market |
| 02316412 | TEVA-IRBESARTAN | TEVA CANADA LIMITED | Tablet | IRBESARTAN 300 MG | Cancelled Post Market |
| 02315971 | TEVA-IRBESARTAN | TEVA CANADA LIMITED | Tablet | IRBESARTAN 75 MG | Cancelled Post Market |
| 02316021 | TEVA-IRBESARTAN/HCTZ | TEVA CANADA LIMITED | Tablet | IRBESARTAN 300 MG; HYDROCHLOROTHIAZIDE 12.5 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37966 | 2026-07-22 | Abbreviated New Drug Submission (ANDS) | Administrative: Licensing Agreement between two manufacturers |
International API supply for IRBESARTAN
18 valid EDQM Certificates of Suitability from 16 holders. 24 active FDA Drug Master Files.
Request a quote for NB-IRBESARTAN HCT